依达拉奉联合奥扎格雷钠治疗急性脑梗死的疗效及对血小板各指标的影响

Study on the curative effect of edaravone combined with sodium ozagrel in the treatment of acute cerebral infarction and effect on platelet parameters

目的探讨依达拉奉联合奥扎格雷钠治疗急性脑梗死的临床疗效及对血小板指标的影响。方法选取2013年2月-2015年3月住院治疗的急性脑梗死患者110例,随机分成A组与B组各55例。2组均予常规治疗,在此基础上A组予依达拉奉联合奥扎格雷钠治疗,B组单用奥扎格雷钠。2周后比较2组治疗前后及2组间的疗效,并分析药物对血小板指标的影响。结果治疗后2组神经功能缺损程度(NIHSS)评分均优于组内治疗前,且A组较B组更优,差异有统计学意义(P<0.05)。治疗后2组凝血酶原时间(PT)及纤维蛋白元(FBG)比较差异无统计学意义(P>0.05);2组血小板分布宽度(PDW)、血小板体积(MPV)明显降低,血小板计数(PLT)升高,与组内治疗前比较差异有统计学意义(P<0.05),且A组较B组更为明显(P<0.05)。A组总有效率96.36%明显高于B组的83.63%,差异均有统计学意义(P<0.05)。结论依达拉奉联合奥扎格雷钠治疗急性脑梗死疗效显著,可影响血小板指标,降低血小板活化,但对PT及FBG无显著影响,提示用药相对安全,值得临床推广应用。

Objective To investigate the curative effect of edaravone combined with sodium ozagrel in the treatment of acute cerebral infarction and effect on platelet parameters. Methods 110 cases of acute cerebral infarction patients were randomly divided into A group （edaravone combined with ozagrel sodium） and B group （single with sodium ozagrel ）,55 cases in each group. The 2 groups were given conventional treatment, and group A was treated with edaravone combined ozagrel sodi- um, group B treated with sodium ozagrel. After 2 weeks, the NIHSS score and clinical effects of the 2 groups were compared, and analysis of the effects of drugs on the platelet index. Results After treatment,the NIHSS scores of the 2 groups were bet- ter than before treatment, and the A group was better than the B group, the difference was statistically significant （P 〈 0.05 ）. After treatment, the two groups platelet distribution width （PDW）, platelet volume （MPV） decreased significantly, the platelet count （PLT） increased, as compared with that before treatment with statistical significance （P 〈 0.05 ）, and in group A than in group B is more obvious, the difference is also statistically significant （P 〈 0.05 ）. The total effective rate of A group was 96. 36% , which was significantly higher than that of the control group （P 〈 0.05 ）. Conclusion Edaravone combined with so- dium ozagrel in the treatment of acute cerebral infarction has a significant effect, Can reduce the platelet activation, but it has no significant effect on prothrombin time and fibrinogen,which is relatively safe, worthy of clinical application.